Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

737
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
737
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

617
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
617
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.9K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TB preventive treatment coverage among children under six years of age in TB-affected households.

IJTLD open·2025
Same author

Prognostic accuracy of whole lung perfusion blood volume as a predictor of 28-day mortality in acute pulmonary thromboembolism - A prospective study.

Lung India : official organ of Indian Chest Society·2025
Same author

Doege Potter syndrome in patient with solitary fibrous tumor of the pleura.

Medical journal, Armed Forces India·2024
Same author

A Case Involving Linezolid-induced Fatal Lactic Acidosis and Pancytopenia.

The Journal of the Association of Physicians of India·2024
Same author

Does serratiopeptidase prevent thoracic surgery in patients of hydropneumothorax of tubercular aetiology?

Lung India : official organ of Indian Chest Society·2024
Same author

Clove stalk aspiration: An unusual cause of chronic cough.

Medical journal, Armed Forces India·2023

Related Experiment Video

Updated: Mar 18, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K

Study of Drug Resistant Pulmonary Tuberculosis.

R B Deoskar1, B Sengupta2, K E Rajan3

  • 1Classified Specialist (Medicine and Respiratory Medicine), Military Hospital, Cardio Thoracic Centre, Pune-40.

Medical Journal, Armed Forces India
|July 14, 2016
PubMed
Summary

Drug resistance in pulmonary tuberculosis (PT) is a significant challenge. This study found that while drug resistance occurs, most patients achieve sputum conversion with reserve drugs, indicating a manageable outcome.

Keywords:
Drug resistant pulmonary tuberculosis

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Related Experiment Videos

Last Updated: Mar 18, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Microbiology

Background:

  • Drug resistance in pulmonary tuberculosis (PT) presents a growing management problem.
  • The incidence of drug-resistant PT necessitates understanding resistance patterns and treatment responses.

Purpose of the Study:

  • To determine the incidence and patterns of drug resistance in pulmonary tuberculosis.
  • To evaluate the treatment response in patients with drug-resistant PT.

Main Methods:

  • Sixty patients with drug-resistant PT were identified from 835 clinically diagnosed cases treated between January 2000 and May 2002.
  • Analysis included incidence, drug resistance patterns, and treatment outcomes, including sputum conversion rates.

Main Results:

  • Drug resistance was found in 7.2% of PT cases, with 14.8% of Mycobacterium tuberculosis strains resistant to at least one antitubercular drug.
  • Initial resistance was noted in 66.7% of cases, while 33.3% developed acquired resistance. Resistance to multiple drugs was common.
  • Sputum conversion was achieved in 98.3% of patients after initiating reserve drugs, with an average conversion time of 10 weeks.

Conclusions:

  • The incidence of drug resistance in this study was lower than reported elsewhere.
  • The majority of drug-resistant PT cases demonstrated satisfactory treatment outcomes with reserve medications.